[EN] ENDOSOMOLYTIC AGENTS FOR GENE THERAPY<br/>[FR] AGENTS ENDOSOMOLYTIQUES POUR THÉRAPIE GÉNIQUE
申请人:UCB BIOPHARMA SPRL
公开号:WO2018060280A1
公开(公告)日:2018-04-05
Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more -NR9-, -O- or -S- linkages, R2 is -YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
式(I)的化合物,其中Ar是一种芳基,可选择性地进一步取代为一个或多个基团R3;A是一个亲脂性、疏水性的基团;R1是一个磷酸二酯、磷酸三酯、硫醚或酰胺基团;X是一个未取代或取代的C6到C24烷基或烯基基团,该基团可被一个或多个-NR9-、-O-或-S-键所中断;R2是-YC(R4)(R5)CO2R6;以及其药学上可接受的盐或溶剂化合物,可用作内体溶解剂,特别用于传递在基因治疗中有用的核酸。